Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1902 | Immunoglobulin Wiki | 0.71 |
| drug3736 | Standard of Care Triple IS Wiki | 0.71 |
| drug3850 | Synthetic neutralising antibodies Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2846 | Peginterferon Lambda-1A Wiki | 0.50 |
| drug4786 | tocilizumab Wiki | 0.50 |
| drug1081 | Corticosteroid Wiki | 0.50 |
| drug4650 | placebo Wiki | 0.18 |
| drug1060 | Convalescent plasma Wiki | 0.15 |
| drug1775 | Hydroxychloroquine Wiki | 0.14 |
| drug4025 | Tocilizumab Wiki | 0.12 |
| drug421 | Azithromycin Wiki | 0.11 |
| drug2916 | Placebo Wiki | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma, Synthetic neutralizing antibodies or Tocilizumab prevents death in patients with COVID-19.
Description: For each pairwise comparison with the 'no additional treatment' arm, the primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality.
Measure: All-cause mortality Time: Within 28 days after randomisationDescription: To assess the effects of study treatment on number of days stay in hospital
Measure: Duration of hospital stay Time: Within 28 days and up to 6 months after the main randomisationDescription: Among patients not on invasive mechanical ventilation at baseline, the number of patients with a composite endpoint of death or need for invasive mechanical ventilation or ECMO.
Measure: Composite endpoint of death or need for mechanical ventilation or ECMO Time: Within 28 days and up to 6 months after the main randomisationDescription: To assess the effects of study treatment on number of patients who needed ventilation and the number of days it was required
Measure: Need for (and duration of) ventilation Time: Within 28 days and up to 6 months after the main randomisationDescription: To assess the effects of study treatment on number of patients who needed renal replacement therapy
Measure: Need for renal replacement Time: Within 28 days and up to 6 months after the main randomisationDescription: To assess the effects of study treatment on number of patients who develop new major cardiac arrythmias
Measure: Development of new major cardiac arrythmias Time: Within 28 days and up to 6 months after the main randomisationThe aim of this study is to reduce COVID-19 related pulmonary complications in adult patients undergoing all types of elective or emergency surgery in a COVID-19 exposed environment. A Trial in Low and Middle Income Countries (LMICs) and A Trial in High Income Countries (HICs)
Description: The primary outcome is any one of the following COVID-19 specific, inpatient, postoperative pulmonary complications: Pneumonia Acute respiratory distress syndrome (ARDS) Death
Measure: Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or death Time: From randomisation until discharge from hospital, average less than 30 daysDescription: Pneumonia will be presented and analysed separately as a secondary outcome measure as well as within the composite primary outcome measure.
Measure: Rate of Pneumonia Time: From randomisation until discharge from hospital, average less than 30 daysDescription: ARDs will be presented and analysed separately as a secondary outcome measure
Measure: Rate of ARDs Time: From randomisation until discharge from hospital, average less than 30 daysDescription: Death will be presented and analysed separately as a secondary outcome measure
Measure: Death rate Time: From randomisation until discharge from hospital, average less than 30 daysDescription: Unexpected inability to extubate and wean patient from ventilation after general anaesthesia, or reintubation and ventilation by 30 days after surgery
Measure: Rate of unexpected ventilation Time: From operation until 30 days post operationDescription: Postoperative diagnosis of proven COVID-19 pulmonary complications
Measure: COVID-19 pulmonary complications Time: 30 days post-surgeryDescription: Overall SARS-CoV-2 infected rate (symptomatic and/or asymptomatic)
Measure: Overall SARS-CoV-2 infected rate Time: 30 days post-surgeryDescription: Duration of hospital stay (including time spent in intensive care, time ventilated)
Measure: Duration of hospital stay Time: 30 days post-surgeryDescription: Pulmonary function in keeping with the World Health Organisation (WHO) Solidarity Trial outcome scale
Measure: Pulmonary function Time: 30 days post-surgeryAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports